Ucyclyd Buphenyl reimbursement to be managed by Corning HTA; orphan drug approved April 30.
Executive Summary
UCYCLYD BUPHENYL REIMBURSEMENT NEGOTIATION TO BE HANDLED BY CORNING HTA following FDA approval of the powder version of the orphan drug for urea cycle disorders April 30. Ucyclyd has contracted with Washington, D.C.-based Corning HTA to conduct a provider-insurance program to assist in transitioning urea cycle patients on Buphenyl (sodium phenylbutyrate) from the clinical trials in which they are currently receiving the drug free of charge to a reimbursement setting with insurance companies, Corning HTA said.